Correction to: Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Correction to: Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma ; day:20 ; month:3 ; year:2024 ; pages:1
Targeted oncology ; (20.3.2024), 1
- Creator
-
France, Nicole L.
Blair, Hannah A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-024-01053-0
- URN
-
urn:nbn:de:101:1-2405212111305.062631442555
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.06.2029, 9:38 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- France, Nicole L.
- Blair, Hannah A.
- SpringerLink (Online service)
Other Objects (12)
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Mean Platelet Volume and Unresectable Hepatocellular Carcinoma
The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma
Correction: Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Correction to: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Mean Platelet Volume and Unresectable Hepatocellular Carcinoma
The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma
Correction: Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Correction to: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience
Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Mean Platelet Volume and Unresectable Hepatocellular Carcinoma
The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma
Correction: Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Correction to: Nanomedicine‐boosting icaritin-based immunotherapy of advanced hepatocellular carcinoma
Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma